 |
| |
| |
 |
| Sirna Therapeutics, Inc. (RNAI) |
OBP IV |
(Acquired by Merck & Co. Inc.)
(Formerly Ribozyme Pharmaceuticals)
San Francisco, CA
www.sirna.com
Sirna develops therapeutics based on RNA interference (RNAi) technology, a new and extremely potent method of using nucleic acids as drugs. Sirna’s technology allows the rapid development of drugs against otherwise challenging drug targets. Currently Sirna has drug development programs in macular degeneration, oncology, diabetes, asthma, dermatology, and other areas.
|
|
 |
| |
 |
| Solexa Inc. |
OBP IV |
(Acquired by Illumina (ILMN))
(Merged with Lynx Therapeutics to form new company, Solexa, Inc.)
Cambridge, U.K. and Hayward, CA
www.solexa.com
Solexa is developing DNA sequencing systems for the comprehensive and economical analysis of whole genomes.
|
|
|
| |
 |
| PowderMed Ltd. |
OBP IV |
(Acquired by Pfizer)
Oxford, United Kingdom
www.powdermed.com
Powdermed Ltd is developing needle-free delivery of therapeutic DNA vaccines and immunomodulators for viral, cancer and other immune disorders.
|
|
|
| |
 |
| Percutaneous Valve Technologies, Inc. |
OBP III |
(Acquired by Edwards Lifesciences (EW))
Fort Lee, NJ
www.pvtechnologies.com
PVT is developing a replacement aortic heart valve capable of percutaneous
transcatheter deployment, thereby creating a new treatment option for patients with aortic
stenosis who can’t undergo open heart surgery.
|
|
|
| |
 |
| Cohesive Technologies Inc. |
OBP III |
(Acquired by Thermo Fisher Scientific (TMO))
Franklin, MA
www.cohesivetech.com
Cohesive Technologies Inc. develops and markets liquid chromatography-based products for the separation, purification, and analysis of drugs from patient samples for the clinical trials and clinical diagnostics markets.
|
|
|
| |
 |
| Zone Labs, Inc. |
OBP III |
(Acquired by Check Point Software (CHKP))
San Francisco, CA
www.zonelabs.com
Zone Labs provides a security software platform for protecting patient and corporate
genetic information.
|
|
|
| |
 |
| ActivX Biosciences |
OBP IV |
(Acquired by Kyorin Pharmaceutical Co., Ltd.)
La Jolla, CA
www.activx.com
ActivX is applying proprietary chemical technologies and high-throughput protein analysis to the drug discovery process.
|
|
|
| |
 |
| Alantos Pharmaceuticals |
OBP IV |
(Acquired by Amgen (AMGN))
(Formerly Therascope AG)
Cambridge, MA and Heidelberg, Germany
www.alantos.com
Alantos is a drug discovery company focused on dynamic combinatorial chemistry, a process which allows the merging of the combinatorial synthesis of new compounds with their screening for target binding into a single step.
|
|
|
| |
 |
| Artemis Pharmaceuticals GmbH (EXEL) |
OBP II |
(Acquired by Exelixis)
Cologne, Germany
www.artemispharma.de
Artemis uses the vertebrate genetic model organisms zebrafish and mouse to identify and
functionally validate novel genes in vivo. The Company was acquired by Exelixis in 2001.
|
|
|
| |
 |
| Artesian Therapeutics, Inc. |
OBP IV |
(Acquired by Cardiome (CRME))
Gaithersburg, MD
www.artesianrx.com
Artesian Therapeutics is developing dual pharmacophore compounds containing proven pharmacophores to treat cardiovascular disease.
|
|
|
| |
 |
| BioSource International Inc. |
OBP IV |
(Acquired by Invitrogen (INVG))
Camarillo, CA
www.biosource.com
BioSource manufactures and markets a wide array of life science assays, biologics and reagents to accelerate the creation of new drug therapies and medical diagnostic methods.
|
|
|
| |
 |
| Cellomics, Inc. |
OBP II |
(Acquired by Fisher Scientific International, Inc.)
Pittsburgh, PA
www.cellomics.com
Cellomics develops and markets high content screening systems for drug screening and localization within living cells.
|
|
|
| |
 |
| Coelacanth Chemical Corporation (LEXG) |
OBP II |
(Acquired by Lexicon Genetics Inc)
The Woodlands, TX
www.lexicon-genetics.com
Coelacanth, which uses proprietary chemistry technologies and knockout mice to rapidly
discover new chemical entities for drug development, recently merged with
Lexicon Genetics and will form the core for a new division called Lexicon
Pharmaceuticals, based in Princeton, N.J. Lexicon Pharmaceuticals will combine
Lexicon's novel, functionally defined targets from the human genome with Coelacanth
Corporation's high performance chemistry technologies to discover new drugs.
|
|
|
| |
|
| CombiChem, Inc. |
OBP II |
(Acquired by DuPont Pharmaceuticals Company)
Wilmington, DE
CombiChem uses combinatorial chemistry to synthesize new drug candidate compounds.
|
|
|
| |
 |
| Corixa Corporation (CRXA) |
OBP IV |
(Merged with and into a wholly owned subsidiary of SmithKline, Beecham Corporation)
Seattle, WA
Corixa Corporation develops therapeutic products for the treatment and prevention of cancer, autoimmune and infectious diseases. BEXXAR®, the Company's most advanced product candidate, is an investigational radioimmunotherapy that combines the targeting ability of a monoclonal antibody and the therapeutic potential of radiation, with patient-specific dosing.
|
|
|
| |
 |
| CytoLogix Corporation |
OBP II, III |
(Primary business acquired by DakoCytomation)
Glostrup, Denmark
www.dako.dk
CytoLogix developed and marketed instruments automating immunohistochemistry and in situ hybridization procedures for the clinical pathology laboratory market. In 2002, DakoCytomation A/S of Glostrup, Denmark acquired the Artisan® instrument business from CytoLogix, Inc. Artisan is a state of the art tissue staining instrument used in pathology labs for cancer diagnosis.
|
|
|
| |
 |
| DATATRAK International (DATA) |
OBP I |
(Formerly Collaborative Clinical Research; Sold to West Corp (NYSE))
Cleveland, OH
www.datatraknet.com
DATATRAK International provides software and related services that allow for the
worldwide electronic transmission of clinical research data for the pharmaceutical
and related life sciences industries.
|
|
|
| |
|
| Familymeds Group, Inc. (FMRX) |
OBP II |
(Merged with DrugMax, Inc.)
Farmington, CT
www.familymeds.com
Familymeds is a hybrid retail pharmacy including both online and apothecary style brick and mortar pharmacies. The merger with DrugMax will combine the specialty pharmacies of Familymeds with DrugMax's specialty distribution channels and aims to close the gaps in the supply chain between manufacturers, doctors and consumers.
|
|
|
| |
 |
| GeneMachines |
OBP III |
(Acquired by the Genomic Solutions subsidiary of Harvard Bioscience, Inc. (HBIO))
San Carlos, CA
GeneMachines is developing instrumentation for the genomics and proteomics markets including a suite of products facilitating the extraction, replication, isolation, and purification of cDNA.
|
|
|
| |
 |
| Hypnion, Inc. |
OBP III |
(Acquired by Eli Lilly and Company (LLY))
Lexington, MA
www.hypnion.com
Hypnion is a genomics drug discovery and development company focused on disorders and regulation of sleep and related CNS diseases.
|
|
|
| |
 |
| Impella CardioSystems AG |
OBP IV |
(Acquired by ABIOMED, Inc. (ABMD))
Aachen, Germany and Danvers, MA
www.abiomed.com
ABIOMED, Inc. develops, manufactures and markets innovative heart assist and replacement systems.
|
|
|
| |
 |
| Microcide Pharmaceuticals, Inc. |
OBP I |
(Merged with Essential Therapeutics)
Mountain View, CA
Microcide develops novel antibiotics to treat infectious diseases.
|
|
|
| |
 |
| Physiome Sciences, Inc. |
OBP II |
(Acquired by Epix Pharmaceuticals)
(Acquired by Predix Pharmaceuticals, Inc.)
Lexington, MA
www.epixmed.com
Epix is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients.
|
|
|
| |
|
| Physiometrix, Inc. |
OBP III |
(Acquired by Hospira, Inc. (HSP))
No. Billerica, MA
Physiometrix designs, manufactures and markets products for use in neurological monitoring during general anesthesia.
|
|
|
| |
|
| Preferred Solutions, Inc. |
OBP I |
(Merged with PacificCare Pharmacy)
New York, NY
Preferred Solutions, Inc. develops software to analyze and control outpatient prescription drug utilization.
|
|
|
| |
|
| Rubicon Medical Corporation (RMDC) |
OBP IV |
(Acquired by and merged into a wholly owned subsidiary of Boston Scientific Corp. (BSX))
Salt Lake City, Utah
Develops embolic protection devices for vascular interventional procedures.
|
|
|
| |
 |
| Signal Pharmaceuticals, LLC |
OBP I |
San Diego, CA
www.signalpharm.com
The Signal Pharmaceuticals, LLC Corp. is identifying new classes of small molecule drugs that selectively regulate disease-associated genes through a corporate strategy that emphasizes (i) integrating advanced target-to-drug discovery technologies and (ii) leveraging drug targets and drug candidates across multiple therapeutic areas.
|
|
|
| |
 |
| Stratagene Corp. (STGN) |
OBP V |
(Acquired by Agilent Technologies)
La Jolla, CA
www.stratagene.com
Stratagene is a worldwide leader in developing innovative products and technologies for life science research.
|
|
|
| |
